article · Eye

Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study

Ashish Sharma
Chitaranjan Mishra
DS Boyer
Adnan Tufail
Tomoko Nakamura
Moayad Shaf’ei
Paolo Lanzetta
C H Lee
Valentina Sarao
Tomoko Ueda‐Consolvo
Marwa Abdelshafy Tabl
Nikulaa Parachuri
Taiji Sakamoto
Tabarak Alsaadi
Debdulal Chakraborty
Clara Vázquez-Alfageme
Mutasem Elfalah
Walid S. Abousaif
Judy E. Kim
Kourous A. Rezaei
Şengül Özdek
Martin S. Spitzer
Ahmed Abdelshafy Tabl
Dilraj S. Grewal
David Eichenbaum
Aleksandra Rachitskaya
Alay Banker
Caroline Baumal
Ahmed A. Shebl
Francesco Bandello
Anat Loewenstein
Nilesh Kumar
Tunde Peto
Atsushi Hayashi
Carl Regillo
Maximilian WM Wintergerst
Giuseppe Querques
Heba T. Rihani
Sobha Sivaprasad
Barbara Parolini
Kodjikian Laurent
Nancy Holekemp
Baruch D. Kuppermann
Martin S. Zinkernagel
Nicolas A. Yannuzzi
Pearse A. Keane
Frank G. Holz
Peter K. Kaiser
Giulia Corradetti
Taku Wakabayashi

2026Benha University

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1038/s41433-026-04537-7

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.

Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study

In plain language

Research topics

Read the original research

Discuss this research